NTRB vs DARE vs AVDL vs MTUS vs CLRB

For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.

8% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). Analysts rate Avadel Pharmaceuticals plc (AVDL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Avadel Pharmaceuticals plc (AVDL) delivered a total return of +164.

9%, compared to -99. 2% for Cellectar Biosciences, Inc. (CLRB). Over 10 years, the gap is even starker: AVDL returned +113. 0% versus CLRB's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avadel Pharmaceuticals plc (AVDL) is the lower-risk stock at 0.

23β versus Cellectar Biosciences, Inc. 's 1. 76β — meaning CLRB is approximately 670% more volatile than AVDL relative to the S&P 500. On balance sheet safety, Metallus Inc. (MTUS) carries a lower debt/equity ratio of 2% versus 4% for Cellectar Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.

8% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to -197. 3% for Metallus Inc.. Over a 3-year CAGR, NTRB leads at -0. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cellectar Biosciences, Inc.

(CLRB) is the more profitable company, earning 0. 0% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MTUS leads at 0. 1% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Metallus Inc.

(MTUS) trades at 20. 1x forward P/E versus 28. 3x for Avadel Pharmaceuticals plc — 8. 2x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Avadel Pharmaceuticals plc (AVDL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

23), +113. 0% 10Y return). Cellectar Biosciences, Inc. (CLRB) carries a higher beta of 1. 76 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVDL: +113. 0%, CLRB: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NTRB (Healthcare) and DARE (Healthcare) and AVDL (Healthcare) and MTUS (Basic Materials) and CLRB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NTRB is a small-cap quality compounder stock; DARE is a small-cap quality compounder stock; AVDL is a small-cap high-growth stock; MTUS is a small-cap quality compounder stock; CLRB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.